Anna Bettini

4.9k total citations · 1 hit paper
27 papers, 876 citations indexed

About

Anna Bettini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Anna Bettini has authored 27 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Anna Bettini's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Anna Bettini is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Anna Bettini collaborates with scholars based in Italy, United States and Greece. Anna Bettini's co-authors include Mirko Marabese, Marina Chiara Garassino, Calogero Lauricella, Gabriella Farina, Massimo Broggini, Silvia Marsoni, Silvio Veronese, Monica Ganzinelli, Roberto Labianca and Eliana Rulli and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Anna Bettini

27 papers receiving 859 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

2013 376 citations Marina Chiara Garassino, Olga Martelli et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Bettini Italy	11	580	574	203	201	95	27	876
Shakun Malik United States	18	454 0.8×	455 0.8×	316 1.6×	259 1.3×	97 1.0×	35	993
A. Misino Italy	11	755 1.3×	368 0.6×	134 0.7×	134 0.7×	106 1.1×	25	983
Xiuwen Guan China	16	559 1.0×	298 0.5×	232 1.1×	411 2.0×	81 0.9×	44	803
J.M.G.H. van Riel Netherlands	14	720 1.2×	415 0.7×	199 1.0×	382 1.9×	67 0.7×	25	989
Ruigang Cai China	17	807 1.4×	391 0.7×	204 1.0×	452 2.2×	76 0.8×	67	1.1k
C McAleer United States	14	535 0.9×	474 0.8×	225 1.1×	151 0.8×	41 0.4×	23	891
F Penault–Llorca France	11	459 0.8×	172 0.3×	194 1.0×	212 1.1×	157 1.7×	35	722
Ashish Gautam United States	11	441 0.8×	406 0.7×	412 2.0×	223 1.1×	180 1.9×	26	899
Lilia Stelmakh Russia	4	935 1.6×	1.1k 1.8×	226 1.1×	159 0.8×	58 0.6×	8	1.2k
Bradley M. Turner United States	14	440 0.8×	197 0.3×	146 0.7×	287 1.4×	103 1.1×	45	759

Countries citing papers authored by Anna Bettini

Since Specialization

Citations

This map shows the geographic impact of Anna Bettini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Bettini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Bettini more than expected).

Fields of papers citing papers by Anna Bettini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Bettini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Bettini. The network helps show where Anna Bettini may publish in the future.

Co-authorship network of co-authors of Anna Bettini

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Bettini. A scholar is included among the top collaborators of Anna Bettini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Bettini. Anna Bettini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mazzotta, Valentina, Giulia Matusali, Eleonora Cimini, et al.. (2024). OC-5 Humoral and cellular immune response after one year from Mpox virus infection. 1 indexed citations

Mandalà, Mario, Paul Lorigan, Barbara Merelli, et al.. (2021). SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. Journal for ImmunoTherapy of Cancer. 9(2). e001694–e001694. 22 indexed citations

Ganzinelli, Monica, Helena Linardou, M.F. Alvisi, et al.. (2021). Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open. 6(1). 100034–100034. 2 indexed citations

Zambelli, Alberto, Vittoria Fotia, Paola Poletti, et al.. (2020). 1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy. Annals of Oncology. 31. S994–S994. 5 indexed citations

Vernieri, Claudio, Monica Ganzinelli, Eliana Rulli, et al.. (2020). LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open. 5(3). e000748–e000748. 5 indexed citations

Bonomi, Lucia, Anna Bettini, Ermenegildo Arnoldi, et al.. (2020). Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report. Tumori Journal. 106(6). NP76–NP78. 5 indexed citations

Bonomi, Maria, Lucia Bonomi, Anna Bettini, et al.. (2016). Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience. Annals of Oncology. 27. iv9–iv9. 1 indexed citations

Rulli, Eliana, Mirko Marabese, Valter Torri, et al.. (2015). Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Annals of Oncology. 26(10). 2079–2084. 40 indexed citations

Bettini, Anna, Jesus G. Ulloa, & Hobart W. Harris. (2015). Appendicitis within Morgagni Hernia and simultaneous Paraesophageal Hernia. BMC Surgery. 15(1). 15–15. 10 indexed citations

10.

Gridelli, Cesare, Filippo de Marinis, Andrea Ardizzoni, et al.. (2014). Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology. 140(10). 1783–1793. 9 indexed citations

11.

Miller, Cynthia L., Anna Bettini, Frederick C. Koerner, et al.. (2014). Surgical excision of radial scars diagnosed by core biopsy may help predict future risk of breast cancer. Breast Cancer Research and Treatment. 145(2). 331–338. 30 indexed citations

12.

Poli, G., Claudia Bianchi, Anna Bettini, et al.. (2013). Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study. Cancer Immunology Research. 1(2). 134–143. 62 indexed citations

13.

Garassino, Marina Chiara, Olga Martelli, Massimo Broggini, et al.. (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The Lancet Oncology. 14(10). 981–988. 376 indexed citations breakdown →

14.

Poli, G., Anna Bettini, Claudia Bianchi, et al.. (2012). Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumors: Preliminary results. 53. 498–498. 3 indexed citations

15.

Garassino, Marina Chiara, Olga Martelli, Anna Bettini, et al.. (2012). TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. Journal of Clinical Oncology. 30(15_suppl). LBA7501–LBA7501. 43 indexed citations

16.

Garassino, Marina Chiara, Olga Martelli, Anna Bettini, et al.. (2012). TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. Journal of Clinical Oncology. 30(18_suppl). LBA7501–LBA7501. 22 indexed citations

17.

Valentini, Umberto, et al.. (2011). Type and trends in outcomes research in breast cancer between 2000 and 2007. Annals of Oncology. 22(10). 2160–2165. 2 indexed citations

18.

Marabese, Mirko, Eliana Rulli, Anna Bettini, et al.. (2011). Abstract B77: KRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLC.. Molecular Cancer Therapeutics. 10(11_Supplement). B77–B77. 4 indexed citations

19.

Bonomi, Lucia, et al.. (2009). 3082 Efficacy of a survaillance dental programm on prevention of osteonecrosis of the jaw in cancer patients with bone metastases: a single institution preliminary experience. European Journal of Cancer Supplements. 7(2). 199–199. 1 indexed citations

20.

Formenti, Silvia C., Darcy Spicer, Kristin A. Skinner, et al.. (2002). Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. International Journal of Radiation Oncology*Biology*Physics. 52(2). 397–405. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact